查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1570812

氨磷汀市場：按產品類型、給藥途徑、應用和最終用戶分類 - 全球預測 2025-2030

Amifostine Market by Product Type (Injection, Powder), Route of Administration (Intravenous, Subcutaneous), Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年氨磷汀市值為5.0325億美元，預計到2024年將達到5.4328億美元，複合年成長率為7.92%，到2030年將達到8.5837億美元。

氨磷汀主要被認為是一種細胞保護劑，因其在化療和放射線治療期間保護正常組織的能力而受到關注。這種藥物對於減少癌症治療的有害副作用至關重要，特別是對於接受積極治療的高風險患者。它的需求在腫瘤學中得到強調，因為它可以減少對健康細胞的損害並提高患者的生活品質。應用範圍擴展到腫瘤專家、醫療機構和專注於癌症治療的研究機構。最終用途範圍廣泛，涵蓋世界各地的醫院和癌症治療中心。

主要市場統計
基準年[2023] 5.0325億美元
預測年份 [2024] 5.4328億美元
預測年份 [2030] 8.5837 億美元
複合年成長率（%） 7.92%

全球癌症發生率不斷上升推動了氨磷汀市場的發展，導致需要能夠最大限度地減少治療副作用的保護劑。癌症治療通訊協定的不斷進步增強了對此類保護解決方案的需求。此外，政府促進癌症治療和支持性護理的措施正在促進市場成長。然而，與氨磷汀使用相關的限制，例如高成本和潛在副作用，可能會阻礙廣泛使用。從業者對其好處的認知有限也可能阻礙成長前景。

新興市場的需求增加，癌症發生率不斷上升，醫療基礎設施不斷發展，帶來了商機。創新途徑包括改進給藥機制和配方，以提高療效和患者依從性。也有潛力探索利用氨磷汀的保護特性進行新的癌症治療的聯合治療。

市場競爭適中，主要由持續的研發活動所推動。將鼓勵涉及癌症藥物的公司投資於對醫療保健提供者進行有關氨磷汀益處的教育，並與研究機構合作進行臨床試驗以擴大其覆蓋範圍。透過解決這些領域，相關人員或許能夠克服市場限制並有效利用成長機會，使氨磷汀在癌症治療領域中佔有更重要的地位。

市場動態：揭示快速發展的氨磷汀市場的關鍵市場洞察

氨磷汀市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 提高醫療保健專業人員對氨磷汀益處的認知
    • 透過擴大新興國家的醫療基礎設施改善獲得治療的機會
    • 增加專注於探索氨磷汀新適應症的臨床試驗
    • 製藥公司之間的策略夥伴關係和聯盟，以加強分銷
  • 市場限制因素
    • 醫療保健提供者和患者對氨磷汀在癌症治療中的效用認知不足
    • 來自替代細胞保護劑的激烈競爭減緩了氨磷汀市場的成長
  • 市場機會
    • 在新的癌症治療方案中擴大氨磷汀作為放射防護劑的使用
    • 氨磷汀與新型化療藥物合併提高療效並減少副作用
    • 氨磷汀在兒科癌症治療的應用越來越多，最大限度地減少了長期放射治療和化療的併發症。
  • 市場挑戰
    • 圍繞著核准氨磷汀用於新型治療用途的監管挑戰導致了重大延誤。
    • 由於氨磷汀學名藥競爭加劇導致價格下降和市場分化

波特的五力：駕馭氨磷汀市場的策略工具

波特的五力架構是了解氨磷汀市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解氨磷汀市場的外部影響

外部宏觀環境因素對氨磷汀市場的表現動態起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解氨磷汀市場的競爭狀況

對 Amifostine 市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣 Amifostine 市場供應商的績效評估

FPNV定位矩陣是評估Amifostine市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了 Amifostine 市場的成功之路

Amifostine 市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 醫護人員對氨磷汀益處的認知不斷增強
      • 透過擴大新興國家的醫療基礎設施改善獲得治療的機會
      • 增加專注於探索氨磷汀新適應症的臨床試驗
      • 透過製藥公司之間的策略聯盟和合作加強分銷
    • 抑制因素
      • 醫療保健專業人員和患者對氨磷汀在腫瘤治療中的益處認知有限
      • 來自替代細胞保護劑的激烈競爭擾亂了氨磷汀市場。
    • 機會
      • 在新的癌症治療通訊協定中擴大氨磷汀作為放射防護劑的使用
      • 氨磷汀與新型化療藥物合併使用可提高治療效果並減少副作用。
      • 擴大氨磷汀在兒童腫瘤學的應用，以盡量減少長期放射線治療和化療的併發症
    • 任務
      • 核准氨磷汀新治療用途的監管挑戰導致了嚴重的延誤
      • 與氨磷汀非專利藥的競爭加劇，導致價格下降和市場分散。
  • 市場區隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 氨磷汀市場：依產品類型

  • 注射
  • 粉末

第7章 氨磷汀市場：依給藥途徑

  • 靜脈
  • 皮下的

第8章 氨磷汀市場：依應用分類

  • 腫瘤學
    • 化療
    • 放射治療
  • 腎臟保護
    • 急性腎損傷
    • 慢性腎臟病

第9章 氨磷汀市場：依最終用戶分類

  • 家庭護理設置
  • 醫院
  • 調查機構
  • 專科診所

第10章 美洲氨磷汀市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章 亞太地區氨磷汀市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲氨磷汀市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議
Product Code: MRR-1A1A064C04E6

The Amifostine Market was valued at USD 503.25 million in 2023, expected to reach USD 543.28 million in 2024, and is projected to grow at a CAGR of 7.92%, to USD 858.37 million by 2030.

Amifostine, primarily known as a cytoprotective agent, has gained attention due to its ability to safeguard normal tissues during chemotherapy and radiation therapy. This drug is essential for reducing the harmful side effects of cancer treatments, especially in high-risk patients undergoing aggressive therapy. Its necessity is emphasized in oncology as it mitigates damage to healthy cells, enhancing patients' quality of life. Application scope extends to oncologists, healthcare facilities, and research institutions focusing on cancer treatments. The end-use scope is vast, encompassing hospitals and cancer treatment centers globally.

KEY MARKET STATISTICS
Base Year [2023] USD 503.25 million
Estimated Year [2024] USD 543.28 million
Forecast Year [2030] USD 858.37 million
CAGR (%) 7.92%

The market for amifostine is driven by the increasing incidence of cancer worldwide, necessitating protective agents that minimize treatment side effects. The continuous advancements in cancer therapeutic protocols reinforce the demand for such protective solutions. Additionally, government initiatives promoting cancer care and supportive treatments enhance market growth. However, growth is challenged by limitations such as high costs associated with amifostine usage and potential adverse effects, which may deter its widespread adoption. Limited awareness among practitioners regarding its benefits may also impede growth prospects.

Opportunities emerge from increasing demand in emerging markets where cancer prevalence is rising and healthcare infrastructures are improving. Innovation pathways include enhancing delivery mechanisms and formulations to improve efficacy and patient compliance. Research into combination therapies that leverage amifostine's protective properties with new cancer treatments also presents potential.

The market is characterized by moderate competition, primarily driven by ongoing research and development activities. Companies involved in oncological therapeutics are encouraged to invest in educating healthcare providers on amifostine benefits and collaborate with research institutions for clinical trials to extend its application scope. By addressing these areas, stakeholders can potentially overcome market limitations and harness growth opportunities effectively, positioning amifostine more prominently within the oncology therapeutic domain.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Amifostine Market

The Amifostine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing awareness among healthcare professionals regarding the benefits of amifostine
    • Expansion of healthcare infrastructure in emerging economies improving treatment access
    • Increasing number of clinical trials focused on exploring new indications for amifostine
    • Strategic partnerships and collaborations between pharmaceutical companies to enhance distribution
  • Market Restraints
    • Limited awareness among healthcare providers and patients about the benefits of amifostine in oncology treatments
    • High competition from alternative cytoprotective agents slowing the growth of the amifostine market
  • Market Opportunities
    • Expanding the use of amifostine as a radioprotective agent in emerging cancer therapy protocols
    • Leveraging amifostine in combination with new chemotherapeutic agents to enhance treatment efficacy and reduce side effects
    • Increasing adoption of amifostine in pediatric oncology to minimize long-term radiotherapy and chemotherapy complications
  • Market Challenges
    • Regulatory challenges concerning the approval of amifostine for new therapeutic uses pose significant delays
    • Increasing competition from generic versions of amifostine leading to price reductions and market fragmentation

Porter's Five Forces: A Strategic Tool for Navigating the Amifostine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Amifostine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Amifostine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Amifostine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Amifostine Market

A detailed market share analysis in the Amifostine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Amifostine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Amifostine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Amifostine Market

A strategic analysis of the Amifostine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Amifostine Market, highlighting leading vendors and their innovative profiles. These include Accela ChemBio Inc., Actiza Pharmaceutical Private Limited, Amneal Pharmaceuticals LLC, Athenex, Inc., Aurobindo Pharma Limited, Cadila Pharmaceuticals Ltd., Cipla Limited, Clinigen Group plc, Dr. Reddy's Laboratories Ltd., Eisai Co., Ltd., Fresenius Kabi USA, LLC, Hikma Pharmaceuticals PLC, MedImmune LLC, Mylan N.V., Natco Pharma Limited, Shanxi Pude Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., West-Ward Pharmaceuticals Corp., and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Amifostine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product Type, market is studied across Injection and Powder.
  • Based on Route of Administration, market is studied across Intravenous and Subcutaneous.
  • Based on Application, market is studied across Oncology and Renal Protection. The Oncology is further studied across Chemotherapy and Radiotherapy. The Renal Protection is further studied across Acute Kidney Injury and Chronic Kidney Disease.
  • Based on End User, market is studied across Homecare Settings, Hospitals, Research Institutes, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing awareness among healthcare professionals regarding the benefits of amifostine
      • 5.1.1.2. Expansion of healthcare infrastructure in emerging economies improving treatment access
      • 5.1.1.3. Increasing number of clinical trials focused on exploring new indications for amifostine
      • 5.1.1.4. Strategic partnerships and collaborations between pharmaceutical companies to enhance distribution
    • 5.1.2. Restraints
      • 5.1.2.1. Limited awareness among healthcare providers and patients about the benefits of amifostine in oncology treatments
      • 5.1.2.2. High competition from alternative cytoprotective agents slowing the growth of the amifostine market
    • 5.1.3. Opportunities
      • 5.1.3.1. Expanding the use of amifostine as a radioprotective agent in emerging cancer therapy protocols
      • 5.1.3.2. Leveraging amifostine in combination with new chemotherapeutic agents to enhance treatment efficacy and reduce side effects
      • 5.1.3.3. Increasing adoption of amifostine in pediatric oncology to minimize long-term radiotherapy and chemotherapy complications
    • 5.1.4. Challenges
      • 5.1.4.1. Regulatory challenges concerning the approval of amifostine for new therapeutic uses pose significant delays
      • 5.1.4.2. Increasing competition from generic versions of amifostine leading to price reductions and market fragmentation
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Amifostine Market, by Product Type

  • 6.1. Introduction
  • 6.2. Injection
  • 6.3. Powder

7. Amifostine Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Intravenous
  • 7.3. Subcutaneous

8. Amifostine Market, by Application

  • 8.1. Introduction
  • 8.2. Oncology
    • 8.2.1. Chemotherapy
    • 8.2.2. Radiotherapy
  • 8.3. Renal Protection
    • 8.3.1. Acute Kidney Injury
    • 8.3.2. Chronic Kidney Disease

9. Amifostine Market, by End User

  • 9.1. Introduction
  • 9.2. Homecare Settings
  • 9.3. Hospitals
  • 9.4. Research Institutes
  • 9.5. Specialty Clinics

10. Americas Amifostine Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Amifostine Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Amifostine Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

LIST OF FIGURES

  • FIGURE 1. AMIFOSTINE MARKET RESEARCH PROCESS
  • FIGURE 2. AMIFOSTINE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL AMIFOSTINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL AMIFOSTINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL AMIFOSTINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL AMIFOSTINE MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL AMIFOSTINE MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL AMIFOSTINE MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL AMIFOSTINE MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS AMIFOSTINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS AMIFOSTINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES AMIFOSTINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES AMIFOSTINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC AMIFOSTINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC AMIFOSTINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA AMIFOSTINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA AMIFOSTINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. AMIFOSTINE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. AMIFOSTINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. AMIFOSTINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL AMIFOSTINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AMIFOSTINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL AMIFOSTINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. AMIFOSTINE MARKET DYNAMICS
  • TABLE 7. GLOBAL AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL AMIFOSTINE MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL AMIFOSTINE MARKET SIZE, BY POWDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL AMIFOSTINE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL AMIFOSTINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL AMIFOSTINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL AMIFOSTINE MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL AMIFOSTINE MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL AMIFOSTINE MARKET SIZE, BY ACUTE KIDNEY INJURY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL AMIFOSTINE MARKET SIZE, BY CHRONIC KIDNEY DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL AMIFOSTINE MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL AMIFOSTINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL AMIFOSTINE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL AMIFOSTINE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS AMIFOSTINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES AMIFOSTINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC AMIFOSTINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. CHINA AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 82. CHINA AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
  • TABLE 83. CHINA AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. INDIA AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. INDIA AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. INDIA AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. INDIA AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 88. INDIA AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
  • TABLE 89. INDIA AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. INDONESIA AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. INDONESIA AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. INDONESIA AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. INDONESIA AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 94. INDONESIA AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
  • TABLE 95. INDONESIA AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. JAPAN AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. JAPAN AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. JAPAN AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. JAPAN AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 100. JAPAN AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
  • TABLE 101. JAPAN AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. MALAYSIA AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. MALAYSIA AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. MALAYSIA AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. MALAYSIA AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 106. MALAYSIA AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
  • TABLE 107. MALAYSIA AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 108. PHILIPPINES AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. PHILIPPINES AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. PHILIPPINES AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. PHILIPPINES AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 112. PHILIPPINES AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. SINGAPORE AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. SINGAPORE AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. SINGAPORE AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. SINGAPORE AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 118. SINGAPORE AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
  • TABLE 119. SINGAPORE AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 120. SOUTH KOREA AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. SOUTH KOREA AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH KOREA AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH KOREA AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH KOREA AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. TAIWAN AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. TAIWAN AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. TAIWAN AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. TAIWAN AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 130. TAIWAN AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
  • TABLE 131. TAIWAN AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 132. THAILAND AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. THAILAND AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. THAILAND AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. THAILAND AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 136. THAILAND AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
  • TABLE 137. THAILAND AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 138. VIETNAM AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. VIETNAM AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. VIETNAM AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. VIETNAM AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 142. VIETNAM AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
  • TABLE 143. VIETNAM AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA AMIFOSTINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 151. DENMARK AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. DENMARK AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. DENMARK AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 154. DENMARK AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 155. DENMARK AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
  • TABLE 156. DENMARK AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 157. EGYPT AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. EGYPT AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. EGYPT AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. EGYPT AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 161. EGYPT AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
  • TABLE 162. EGYPT AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. FINLAND AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. FINLAND AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. FINLAND AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 166. FINLAND AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 167. FINLAND AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
  • TABLE 168. FINLAND AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 169. FRANCE AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. FRANCE AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. FRANCE AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. FRANCE AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 173. FRANCE AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
  • TABLE 174. FRANCE AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. GERMANY AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. GERMANY AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 177. GERMANY AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 178. GERMANY AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 179. GERMANY AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
  • TABLE 180. GERMANY AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. ISRAEL AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. ISRAEL AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. ISRAEL AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. ISRAEL AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 185. ISRAEL AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
  • TABLE 186. ISRAEL AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. ITALY AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. ITALY AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. ITALY AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. ITALY AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 191. ITALY AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
  • TABLE 192. ITALY AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 193. NETHERLANDS AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. NETHERLANDS AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 195. NETHERLANDS AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 196. NETHERLANDS AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 197. NETHERLANDS AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
  • TABLE 198. NETHERLANDS AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 199. NIGERIA AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. NIGERIA AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 201. NIGERIA AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 202. NIGERIA AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 203. NIGERIA AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
  • TABLE 204. NIGERIA AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 205. NORWAY AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. NORWAY AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 207. NORWAY AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 208. NORWAY AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 209. NORWAY AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
  • TABLE 210. NORWAY AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 211. POLAND AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. POLAND AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 213. POLAND AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 214. POLAND AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 215. POLAND AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
  • TABLE 216. POLAND AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 217. QATAR AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. QATAR AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 219. QATAR AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 220. QATAR AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 221. QATAR AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
  • TABLE 222. QATAR AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 223. RUSSIA AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. RUSSIA AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 225. RUSSIA AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 226. RUSSIA AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 227. RUSSIA AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
  • TABLE 228. RUSSIA AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 229. SAUDI ARABIA AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. SAUDI ARABIA AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 231. SAUDI ARABIA AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 232. SAUDI ARABIA AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 233. SAUDI ARABIA AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
  • TABLE 234. SAUDI ARABIA AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 235. SOUTH AFRICA AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. SOUTH AFRICA AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 237. SOUTH AFRICA AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 238. SOUTH AFRICA AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH AFRICA AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH AFRICA AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 241. SPAIN AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. SPAIN AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 243. SPAIN AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 244. SPAIN AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 245. SPAIN AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
  • TABLE 246. SPAIN AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 247. SWEDEN AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. SWEDEN AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 249. SWEDEN AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 250. SWEDEN AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 251. SWEDEN AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
  • TABLE 252. SWEDEN AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 253. SWITZERLAND AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 254. SWITZERLAND AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 255. SWITZERLAND AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 256. SWITZERLAND AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 257. SWITZERLAND AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
  • TABLE 258. SWITZERLAND AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 259. TURKEY AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. TURKEY AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 261. TURKEY AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 262. TURKEY AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 263. TURKEY AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
  • TABLE 264. TURKEY AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 265. UNITED ARAB EMIRATES AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. UNITED ARAB EMIRATES AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 267. UNITED ARAB EMIRATES AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 268. UNITED ARAB EMIRATES AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 269. UNITED ARAB EMIRATES AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
  • TABLE 270. UNITED ARAB EMIRATES AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 271. UNITED KINGDOM AMIFOSTINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED KINGDOM AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED KINGDOM AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED KINGDOM AMIFOSTINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED KINGDOM AMIFOSTINE MARKET SIZE, BY RENAL PROTECTION, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED KINGDOM AMIFOSTINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 277. AMIFOSTINE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 278. AMIFOSTINE MARKET, FPNV POSITIONING MATRIX, 2023